Health
Aid groups highlight pediatric treatment gaps in ongoing Ebola outbreak
Deutsche Welle reports that young children face high mortality and frequent exclusion from Ebola trials.
The short version
- Doctors Without Borders reports that children under age 5 face a mortality rate exceeding 60% in the Democratic Republic of Congo's Ebola outbreak.[Deutsche Welle]
- Initial clinical studies evaluating the antiviral drug obeldesivir excluded young children weighing under 30 kilograms.[Deutsche Welle]
- Alternative intravenous treatments like remdesivir remain hard to administer to children during active disease outbreaks.[Deutsche Welle]
- Health experts urge pharmaceutical companies to include pediatric populations earlier, noting trials often prioritize adults to reduce costs.[Deutsche Welle]
Key facts
- The mortality rate for children under 5 in the current Democratic Republic of Congo Ebola outbreak exceeds 60%, according to Doctors Without Borders.[Deutsche Welle]
- Children weighing under 30 kilograms and aged 12 or younger were excluded from the original EBO-PEP clinical study assessing obeldesivir.[Deutsche Welle]
- Administering a 10-day intravenous infusion regimen of remdesivir during an outbreak is particularly difficult for young children.[Deutsche Welle]
- An American doctor's family treated prophylactically in Berlin with MBP134 showed no apparent side effects and remained healthy.[Deutsche Welle]
- Marc Biot stated pharmaceutical companies often deprioritize pediatric trials because adult-only studies are faster and cheaper.[Deutsche Welle]
What remains uncertain
- It remains unverified whether the experimental antibody treatment MBP134 prevented infection in the exposed children in Berlin due to the small sample size.[Deutsche Welle]
Sources
Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.